These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 17387702

  • 1. Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.
    Turello R, Rentsch K, Di Paolo E, Popovic MB.
    Pediatr Blood Cancer; 2008 Jan; 50(1):154-6. PubMed ID: 17387702
    [Abstract] [Full Text] [Related]

  • 2. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
    Müller J, Kralovánszky J, Adleff V, Pap E, Németh K, Komlósi V, Kovács G.
    Anticancer Res; 2008 Jan; 28(5B):3051-4. PubMed ID: 19031955
    [Abstract] [Full Text] [Related]

  • 3. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
    van Kooten Niekerk PB, Schmiegelow K, Schroeder H.
    Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
    [Abstract] [Full Text] [Related]

  • 4. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
    Seidemann K, Book M, Zimmermann M, Meyer U, Welte K, Stanulla M, Reiter A.
    Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
    [Abstract] [Full Text] [Related]

  • 5. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
    Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, Bacci G, Craft AW, Adamson PC.
    Cancer; 2004 May 15; 100(10):2222-32. PubMed ID: 15139068
    [Abstract] [Full Text] [Related]

  • 6. Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism.
    Strunk T, Gottschalk S, Goepel W, Bucsky P, Schultz C.
    Med Pediatr Oncol; 2003 Jan 15; 40(1):48-50. PubMed ID: 12426687
    [No Abstract] [Full Text] [Related]

  • 7. Methylenetetrahydrofolate reductase gene polymorphism and glucocorticoid intake in children with ALL and aseptic osteonecrosis.
    Bernbeck B, Mauz-Körholz C, Zotz RB, Göbel U.
    Klin Padiatr; 2003 Jan 15; 215(6):327-31. PubMed ID: 14677097
    [Abstract] [Full Text] [Related]

  • 8. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients.
    Lambrecht L, Sleurs C, Labarque V, Dhooge C, Laenen A, Sinnaeve F, Renard M, Uyttebroeck A.
    Pharmacogenomics; 2017 Jun 15; 18(8):787-795. PubMed ID: 28592186
    [Abstract] [Full Text] [Related]

  • 9. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
    Zheng MM, Yue LJ, Chen XW, Wen FQ, Li CG, Yang CL, Xie C, Ding H.
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar 15; 15(3):201-6. PubMed ID: 23498762
    [Abstract] [Full Text] [Related]

  • 10. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
    Haase R, Elsner K, Merkel N, Stiefel M, Mauz-Körholz C, Kramm CM, Körholz D.
    Klin Padiatr; 2012 Apr 15; 224(3):156-9. PubMed ID: 22513795
    [Abstract] [Full Text] [Related]

  • 11. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
    Cózar Olmo JA, Martínez Colmenero C, Peláez Pleguezuelos I, Leiva Gea I, López García AB, de la Cruz Moreno J.
    An Pediatr (Barc); 2009 Sep 15; 71(3):230-4. PubMed ID: 19617010
    [Abstract] [Full Text] [Related]

  • 12. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
    Cecyn KZ, Lee J, Oguro T, Petrilli AS, Bordin JO.
    Am J Hematol; 2003 Mar 15; 72(3):209-11. PubMed ID: 12605394
    [Abstract] [Full Text] [Related]

  • 13. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB, Mdhaffar M, Frikha R, Ghozzi H, Hakim A, Sahnoun Z, Elloumi M, Zeghal K.
    Adv Clin Exp Med; 2018 Aug 15; 27(8):1061-1068. PubMed ID: 29911750
    [Abstract] [Full Text] [Related]

  • 14. Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism.
    Gammon DC, Bhatt MS, Patel B, Anderson M, Van Horn A, Glantz MJ.
    J Oncol Pharm Pract; 2008 Sep 15; 14(3):153-6. PubMed ID: 18719070
    [Abstract] [Full Text] [Related]

  • 15. Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury.
    Mahadeo KM, Dhall G, Panigrahy A, Lastra C, Ettinger LJ.
    Pediatr Hematol Oncol; 2010 Feb 15; 27(1):46-52. PubMed ID: 20121554
    [Abstract] [Full Text] [Related]

  • 16. [Effect of GSTP1 and MTHFR Gene Polymorphism on Side Effects of HD-MTX in ALL Children].
    Li F, Yin DD, Zhou XL, Ma JM, Guo HM, Meng L.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun 15; 25(3):723-728. PubMed ID: 28641625
    [Abstract] [Full Text] [Related]

  • 17. Significant impact of MTHFR C677T polymorphism on plasma homovanillic acid (HVA) levels among alcohol-dependent patients.
    Lutz UC, Batra A, Wiatr G, Machicao F, Kolb W, Maurer S, Buchkremer G, Köhnke MD.
    Addict Biol; 2007 Mar 15; 12(1):100-5. PubMed ID: 17407503
    [Abstract] [Full Text] [Related]

  • 18. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T, Mellgren K, Harila-Saari A, Åsberg A, Kanerva J, Jónsson Ó, Vaitkeviciene G, Stamm Mikkelssen T, Schmiegelow K, Heldrup J.
    Pediatr Blood Cancer; 2017 Jul 15; 64(7):. PubMed ID: 27966809
    [Abstract] [Full Text] [Related]

  • 19. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
    Patiño-García A, Zalacaín M, Marrodán L, San-Julián M, Sierrasesúmaga L.
    J Pediatr; 2009 May 15; 154(5):688-93. PubMed ID: 19159907
    [Abstract] [Full Text] [Related]

  • 20. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
    Salazar J, Altés A, del Río E, Estella J, Rives S, Tasso M, Navajas A, Molina J, Villa M, Vivanco JL, Torrent M, Baiget M, Badell I.
    Pharmacogenomics J; 2012 Oct 15; 12(5):379-85. PubMed ID: 21747412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.